住院成人药物预防基础上加用间歇充气加压装置预防静脉血栓栓塞:系统评价与Meta分析
该系统评价与Meta分析纳入17项随机对照试验、共8796例住院成人,比较药物血栓预防联合间歇充气加压装置与单用药物血栓预防。联合组静脉血栓栓塞风险降低(15项试验,RR=0.53,95%CI 0.35-0.81),深静脉血栓风险降低(14项试验,RR=0.52,95%CI 0.33-0.81),肺栓塞无显著差异(7项试验,RR=0.73,95%CI 0.32-1.68)。全因死亡和不良事件分别有中等质量和极低质量证据提示联合间歇充气加压不太可能改变其风险。作者认为证据质量低,需进一步开展大型高质量随机试验以支持其使用并识别可能获益的亚组。
要点
- 住院成人药物血栓预防基础上加用间歇充气加压装置,静脉血栓栓塞风险降低(15项试验,RR=0.53,95%CI 0.35-0.81),证据质量低。
- 联合间歇充气加压装置使深静脉血栓风险降低(14项试验,RR=0.52,95%CI 0.33-0.81),证据质量低。
- 联合间歇充气加压装置未显著降低肺栓塞风险(7项试验,RR=0.73,95%CI 0.32-1.68)。
- 中等和极低质量证据分别提示联合间歇充气加压不太可能改变全因死亡或不良事件风险。
- 亚组分析提示在行业资助的试验中获益更明显。
适用人群与场景
- 住院成人患者,已接受药物血栓预防;纳入的随机对照试验比较药物血栓预防联合间歇充气加压装置与单用药物血栓预防。
处置流程与药物剂量
- 间歇充气加压装置大多应用至大腿,药物血栓预防主要为低分子量肝素。
研究设计与关键结果
- 系统评价与Meta分析,纳入17项随机对照试验、8796例住院成人,比较药物血栓预防联合间歇充气加压装置与单用药物血栓预防。
- 联合间歇充气加压装置与静脉血栓栓塞风险降低相关(15项试验,RR=0.53,95%CI 0.35-0.81)。
- 联合间歇充气加压装置与深静脉血栓风险降低相关(14项试验,RR=0.52,95%CI 0.33-0.81)。
- 联合间歇充气加压装置与肺栓塞风险无显著差异(7项试验,RR=0.73,95%CI 0.32-1.68)。
- 中等质量证据提示联合间歇充气加压装置不太可能改变全因死亡风险;极低质量证据提示不太可能改变不良事件风险。
- 亚组分析提示在行业资助的试验中获益更明显。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入17项随机对照试验。
- 采用Cochrane随机试验偏倚风险评估工具第2版评估偏倚风险,采用GRADE方法评估证据质量。
- 静脉血栓栓塞和深静脉血栓结局的证据质量评为低,因偏倚风险和 inconsistency(不一致性)降级。
- 全因死亡结局为中等质量证据;不良事件结局为极低质量证据。
- 局限:证据质量低;亚组分析提示行业资助试验中获益更明显;作者认为需进一步开展大型高质量随机试验以支持其使用并识别可能获益的患者亚组。
对床旁实践的改变
- 作者认为,在药物血栓预防基础上加用间歇充气加压装置预防静脉血栓栓塞和深静脉血栓的证据质量低,需进一步大型高质量随机试验支持其使用并识别可能获益的亚组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Venous thromboembolic events (VTE) are frequent complications in hospitalized patients and a leading cause of preventable death in hospital. Pharmacologic prophylaxis is a standard of care to prevent VTE in patients at risk, the additional value of intermittent pneumatic compression (IPC) is uncertain. We aimed to evaluate the efficacy of adding IPC to pharmacologic prophylaxis to prevent VTE in hospitalized adults.
DATA SOURCES: We searched the Cochrane Central Register of Controlled Trials, Embase, MEDLINE, Cumulative Index to Nursing and Allied Health Literature, ClinicalTrials.gov, and the International Clinical Trials Registry Platform from inception to July 2022.
STUDY SELECTION: We included randomized controlled trials comparing the use of IPC in addition to pharmacological thromboprophylaxis to pharmacological thromboprophylaxis alone in hospitalized adults.
DATA EXTRACTION: Meta-analyses were performed to calculate risk ratio (RR) of VTE, deep venous thrombosis (DVT), and pulmonary embolism (PE). We assessed the risk of bias using the Cochrane Risk of Bias Tool for Randomized Trials, Version 2 and the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach.
DATA SYNTHESIS: We included 17 trials enrolling 8,796 participants. The IPC was mostly applied up to the thigh and pharmacological thromboprophylaxis was primarily low-molecular-weight heparin. Adjunctive IPC was associated with a decreased risk of VTE (15 trials, RR = 0.53; 95% CI [0.35-0.81]) and DVT (14 trials, RR = 0.52; 95% CI [0.33-0.81]) but not PE (seven trials, RR = 0.73; 95% CI [0.32-1.68]). The quality of evidence was graded low, downgraded by risk of bias and inconsistency. Moderate and very low-quality evidence, respectively, suggests that adjunctive IPC is unlikely to change the risk of all-cause mortality or adverse events. Subgroup analyses indicate a more evident apparent benefit in industry-funded trials.
CONCLUSIONS: Results indicate low-quality evidence underpinning the additional use of IPC to pharmacological thromboprophylaxis for prevention of VTE and DVT. Further large high-quality randomized trials are warranted to support its use and to identify patient subgroups for whom it could be beneficial.
参考来源
- Duval C, Sirois C, Savoie-White FH, et al. Effect of Intermittent Pneumatic Compression in Addition to Pharmacologic Prophylaxis for Thromboprophylaxis in Hospitalized Adult Patients: A Systematic Review and Meta-Analysis. Crit Care Explor. 2022. PMID: 36212735. doi:10.1097/CCE.0000000000000769
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。